For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/itch-scratch-immunotherapies-for-prurigo-nodularis-8912
Featuring faculty Shawn Kwatra, MD, moderated by Gregg Sherman, MD
Summary
Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe, unrelenting pruritus that is higher in intensity and associated with greater decrease in quality of life (QoL) than with other pruritic dermatoses such as atopic dermatitis and psoriasis. Patients with PN report severe disturbances in sleep, reduced participation in social activities, and absenteeism from work because of their disease. Outcomes with traditional treatments for PN are variable and unpredictable but novel and emerging therapies, that target the underlying pathophysiology of PN, offer patients opportunities for an improved quality of life.
In this second of two podcast episodes, Dr. Shawn Kwatra and Dr. Gregg Sherman discuss the pathophysiology of PN and how to incorporate recently approved and emerging therapies into the management of this condition. Joining them is a real patient with PN to share their journey and the impact of systemic therapy.
This podcast was recorded and is being used with permission of the presenters.
Learning Objectives
Upon completion of this activity, learners should be able to:
This activity is accredited for CME/CE Credit.
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).
Click on the link to view the summary of individual disclosures.
https://docs.naceonline.com/wp-content/uploads/sites/16/2023/07/Summary-of-Individual-Disclosures.pdf
Disclosure of Commercial Support
This educational activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.